Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bridging Trial of Glepaglutide Autoinjector vs Vial/Syringe
NCT04318743Phase 1Completed
- Sponsor
- Zealand Pharma
- Start
- Mar 2020
- Primary completion
- Jun 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of glepaglutide in short bowel syndrome (SBS) (3 arms), sponsored by Zealand Pharma. Primary endpoint: Pharmacokinetic Variables. Started Mar 2020; status: completed.
02
Drugs
glepaglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT04318743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04318743.